Choosing Wisely, the initiative for medical cost-effectiveness (don't call it rationing!) of the American Board of Internal Medicine, included the use of vasodilators for pulmonary hypertension owing to left heart disease or hypoxemic lung disease (WHO Groups II and III) as #2 on its top five "no-no's" in its new pulmonology section.